A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of Subcutaneous AZD6912 in Healthy Participants

Exclusion Criteria

• • History of any clinically important disease or disorder.
• • Current or recurrent disease of clinical significance that could affect clinical assessments or clinical laboratory evaluations.
• • Any clinically important illness, medical/surgical procedure or trauma within 4 weeks of the first administration of study intervention.
• • History of congenital or acquired immunodeficiency or complement deficiency or an underlying condition that predisposes to infection.
• • History of any Neisseria infection, unexplained, recurrent infections, or infection requiring treatment with systemic antibiotics.
• • Evidence of hepatitis B infection (positive for HBsAg or positive for anti-HBcAb) or hepatitis C viral infection (HCV Abs or hepatitis C RNA positive) or HIV infection (positive for HIV type 1 or type 2 Abs).
• • Participants testing positive for COVID-19 prior to dosing.
• • Any cardiac abnormalities.
• • A CAP activity < 60% at screening.
• • Known or suspected history of drug abuse, history of alcohol abuse or smoking.